DRC Kft.
- Address
- lock Available on a paid plan
Cardiovascular and Metabolic Research at DRC Kft.
Clinical trials at this Balatonfured research site focus strongly on cardiovascular diseases and nutritional and metabolic disorders, with studies in heart failure, atherosclerotic cardiovascular disease, hypertension, dyslipidemia, hypertriglyceridemia, obesity, and type 2 diabetes. The main goal is to evaluate new treatment options and improve long-term disease control and risk reduction.
- Testing new approaches for heart failure prevention and treatment
- Evaluating therapies for high blood pressure and resistant hypertension
- Studying medicines for high cholesterol, mixed dyslipidemia, and severe hypertriglyceridemia
- Assessing treatments aimed at weight management and glucose control
These studies reflect a broad effort to address major cardiometabolic risks through better prevention, symptom control, and outcome improvement.
Inflammatory and Immune-Mediated Disease Studies
Another important area of research covers immune system diseases, especially atopic dermatitis, Crohn’s disease, and ulcerative colitis. Trials in this field are designed to assess whether newer therapies can better manage chronic inflammation, reduce symptoms, and support longer-term disease control.
- Exploring treatments for atopic dermatitis and related skin inflammation
- Evaluating therapies for Crohn’s disease and ulcerative colitis
- Measuring the safety and effectiveness of long-term anti-inflammatory care
At DRC Kft., these trials help advance options for patients living with persistent immune-driven conditions that can affect daily life and overall well-being.
Respiratory and Allergy Research
The site also participates in studies on respiratory tract diseases and otorhinolaryngologic diseases, including chronic obstructive pulmonary disease, refractory chronic cough, and birch pollen-induced allergic rhinoconjunctivitis. This research aims to improve symptom relief, breathing comfort, and quality of life for people with chronic airway and allergy-related conditions.
- Testing new options for COPD symptom control and clinical outcomes
- Studying treatments for chronic cough, including unexplained cases
- Evaluating therapies for seasonal allergy and nasal-eye allergy symptoms
These projects show a focus on better management of common but often difficult-to-treat respiratory and allergy disorders.
Specialized Investigations Across Complex Conditions
DRC Kft. supports a diverse portfolio that links congenital, hereditary, and neonatal disease research with broader chronic disease care, while also addressing overlapping conditions such as chronic kidney disease, systemic inflammation, and obesity-related cardiovascular risk. The studies are generally aimed at finding more effective therapies and understanding how multiple health problems interact over time.
- Investigating treatments in patients with kidney impairment and heart failure
- Studying care strategies for obesity combined with diabetes or cardiovascular disease
- Exploring therapies for conditions with shared inflammatory and metabolic features
With 30 trials and 17 investigators, the site contributes to clinical research that spans prevention, symptom management, and long-term disease improvement across several major therapeutic areas.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 9 therapeutic areas and 15 of 64 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 64 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 9 by active trials.
- 1AstraZeneca AB4active
lock +8 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB6trials
lock +8 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in DRC Kft.
lock Showing 1 of 45 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 52-week randomized, double-blind, placebo-controlled, multi-center Phase 2b study with a 52-week blinded extension and an optional open-label extension—assessing the safety and efficacy of frexalimab, a CD40L-antagonist monoclonal antibody, for the preservation of pancreatic β-cell function in adults and adolescents with newly diagnosed type 1 diabetes on insulin therapy | Sanofi-Aventis Recherche & Developpement | Phase II | Not Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 64 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Inclisiran | 3 | Unknown | 2021-11-26 | 2023-09-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.